| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S654840-1ml |
1ml |
期货  |
|
| 规格或纯度 | 10mM in DMSO |
|---|---|
| 英文名称 | SRPKIN-1 |
| 生化机理 | SRPKIN-1 是一种共价且不可逆的 SRPK1/2 抑制剂，其 IC 50 s 分别为 35.6 和 98 nM。抗血管生成作用。 |
| 储存温度 | 充氩,-80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC 50 s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect In Vitro SRPKIN-1 treatment at 200 nM (10, 50, 100, 200 nM, 16 hours) significantly reduces SR protein phosphorylation at the steady state with or without washout. ? SRPK-IN-1 potently converts VEGF from pro-angiogenic to anti-angiogenic isoform. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Ba/F3 cells Concentration: 0-10000 nM Incubation Time: 72 h Result: Potently decreased the level of SR phosphorylation in a dose-dependent manner, leading to increased VEGF-A165b RNA as well as protein even at a dose of 200 nM. In Vivo SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis in a CNV mouse model through VEGF alternative splicing . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 50 nM, 300 nM, 1 μL Administration: Intravitreal injection, 5 times Result: SRPKIN-1-treated mice is significantly suppressed in a dose-dependent manner based upon measurement of the CNV area . IC50& Target:IC50: 35.6 nM (SRPK1), 98 nM (SRPK2) |
| 分子类型 | 未知 |
|---|---|
| Isomeric SMILES | CCC1=CC2=C(C=C1C3=CC(=CC=C3)S(=O)(=O)F)C(C4=C(C2=O)C5=C(N4)C=C(C=C5)C#N)(C)C |
| PubChem CID | 135324340 |
| 分子量 | 472.53 |
首页
400-620-6333
